Qureight appoints Rebecca Simmons as Chief Operating Officer
Qureight appoints Dr Steven Bishop as Chief Medical Officer
Qureight Vascul8 model for pulmonary vascular disorders validated in peer-reviewed study, offering potential to improve treatment options and patient outcomes following surgery
Qureight has major presence at 2025 ERS Congress to highlight how advanced imaging biomarkers and AI are transforming interstitial lung disease research and drug development
Appointment of Professor Tamera Corte to Qureight's Scientific Advisory Committee.
Qureight appoints Craig Rhodes as Head of Partnerships to lead on pharma relationship management
Qureight’s AI 3D imaging platform to support Calluna Pharma’s Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF)
Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion
Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment
Qureight partners With Cumberland Pharmaceuticals to advance innovative Idiopathic Pulmonary Fibrosis treatment research
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
Qureight showcases the power of AI-driven image analytics across eight presentations at the 2025 ATS International Conference
Appointment of Dr. Paul Ford MD, PhD as Senior Clinical Development Advisor
Qureight Board of Directors elects Dr. Neil Johnston to the Board as Non-Executive Chair
Qureight and Remedy Cell partner to integrate deep learning platform into Phase 1b study of RC-0315 in IPF
Qureight Appoints Patrick Driscoll as Chief Financial Officer
Starting 2025 on a high!
